Replies to post #89751 on Biotech Values

[DewDiligence]

What’s Up With JNJ’s Pharma Division?

As Procrit/Eprex continues to slide in sync with AMGN’s woes in the EPO
market, JNJ’s pharma division is being driven by one mega-blockbuster,
Remicade, and a bevy of “specialty” products such as Velcade, the HIV
protease inhibitor, Prezista, and Risperdal Consta, which continues to
perform well despite the availability of oral Risperdal as a generic.

The dominance of JNJ’s numbers by Remicade is troubling insofar as the
RA/autoimmune category is becoming ever more crowded. (Simponi, JNJ’s
follow-on to Remicade, is having a tough time gaining traction and is not
yet big enough to be included in the table below.)

Best bets for a new JNJ mega-blockbuster? Xarelto and Telaprevir (IMO).

Below are the worldwide sales of JNJ’s biggest-selling drugs in 1Q10:

 
                                  Sales    YoY 
                   Indication     (MUSD) %Change 
 Remicade*         RA/autoimmune  1,200     15% 
 Procrit/Eprex     Anemia           523     -5% 
 Risperdal Consta  Schizophrenia    379     17% 
 Levaquin/Floxin   Antibiotic       371    -13% 
 Concerta          ADHD             329     -4% 
 Velcade           Mltple myeloma   261     36% 
 Aciphex/Pariet    Heartburn        260     -1% 
 Prezista          HIV              187     53% 
 Duragesic†        Pain             184    -20%† 
 Topamax†          Epilepsy         148    -75%† 
 Risperdal†        Schizophrenia    138    -50%† 
 ALL OTHER                        1,660     n/a 
 ================                 =====    ==== 
 TOTAL                            5,640     -3% 
  
 *US sales only (MRK has ex-US rights). 
 †Off-patent.

Source: http://finance.yahoo.com/news/Johnson-Johnsons-topselling-apf-1813294344.html?x=0